The drug development process is costly, time consuming and laden with risk—with only 1% of drugs making it from pre-clinical all the way to market, according to Pharma Intelligence. To beat these odds, life sciences leaders must know when to continue funding a promising, new product and when to call it quits.
Tune in for insights into:
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More